Clinical Trials on Epidermolysis Bullosa Simplex Kobner

Total 128 results

Castle Creek Pharmaceuticals, LLC

Completed

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Dystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)

United States
TWi Biotechnology, Inc.

Recruiting

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex

United States, Taiwan, Australia, Philippines
Stanford University

Completed

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Epidermolysis Bullosa Simplex | Epidermolysis Bullosa Simplex Kobner | Weber-Cockayne Syndrome

United States
Premier Specialists, Australia

Unknown

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Epidermolysis Bullosa Simplex | Epidermolysis Bullosa Simplex Kobner | Weber-Cockayne Syndrome

Australia
Centre Hospitalier Universitaire de Nice

Completed

Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara

Epidermolysis Bullosa Simplex Dowling Meara

France
Joyce Teng

Recruiting

Computational Drug Repurposing for All EBS Cases

Healthy | Epidermolysis Bullosa | Genetic Skin Disease | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, Junctional

United States
InMed Pharmaceuticals Inc.

Completed

INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, Junctional | Kindler Syndrome

France, Germany, Greece, Israel, Italy
ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa

Epidermolysis Bullosa | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex

United States
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Castle Creek Pharmaceuticals, LLC

Completed

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Epidermolysis Bullosa | Epidermolysis Bullosa Simplex

United States
Centre Hospitalier Universitaire de Nice

Unknown

Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin

Epidermolysis Bullosa

France
Castle Creek Pharmaceuticals, LLC

Terminated

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Epidermolysis Bullosa Simplex

United States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
Tel-Aviv Sourasky Medical Center

Unknown

Diacerin for the Treatment of Epidermolysis Bullosa Simplex

Epidermolysis Bullosa Simplex
Lenus Therapeutics, LLC

Terminated

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (CELEB)

Dystrophic Epidermolysis Bullosa | Junctional Epidermolysis Bullosa

United States
National Medical Research Center for Children's...

Active, not recruiting

The State of Sexual Development in Children With Inherited Epidermolysis Bullosa

Epidermolysis Bullosa | Hormone Disturbance | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Dermatologic Disease | Epidermolysis Bullosa, Junctional | Puberty Disorders | Kindler Syndrome

Russian Federation
Krystal Biotech, Inc.

Completed

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB (GEM-3)

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa

United States
Castle Creek Biosciences, LLC.

Terminated

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa Dystrophica, Recessive

United States
Instituto de Investigación Hospital Universitario...
Instituto de Salud Carlos III; Universidad Carlos III Madrid (TERMeG); St John... and other collaborators

Unknown

Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica, Recessive

Spain
Holostem Terapie Avanzate s.r.l.
IRCCS San Raffaele; University of Modena and Reggio Emilia

Recruiting

Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa (HOLOGENE 5)

Junctional Epidermolysis Bullosa Non-Herlitz Type

France, Italy
Krystal Biotech, Inc.

Recruiting

Long-Term Follow-up Protocol

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa

United States
University Hospital, Toulouse

Recruiting

Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex (EBTox)

Epidermolysis Bullosa Simplex

France
BioMendics, LLC

Completed

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)

Epidermolysis Bullosa Simplex

United States
University of Southern California

Recruiting

Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Recessive Dystrophic Epidermolysis Bullosa

United States
Stanford University

Recruiting

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica

United States
Phoenix Tissue Repair, Inc.

Completed

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) (PTR-01-001)

Recessive Dystrophic Epidermolysis Bullosa

United States
Institut National de la Santé Et de la Recherche...

Unknown

Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) (RDEB)

Recessive Dystrophic Epidermolysis Bullosa

France, United Kingdom
Phoenicis Therapeutics

Not yet recruiting

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Dystrophic Epidermolysis Bullosa

United States
Thomas Jefferson University
Onconova Therapeutics, Inc.

Recruiting

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Recessive Dystrophic Epidermolysis Bullosa

United States
Castle Creek Biosciences, LLC.

Active, not recruiting

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (DEFI-RDEB)

Recessive Dystrophic Epidermolysis Bullosa

United States
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, a BridgeBio company

Completed

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Recessive Dystrophic Epidermolysis Bullosa

United States
RHEACELL GmbH & Co. KG
FGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & Services

Completed

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Recessive Dystrophic Epidermolysis Bullosa

United States, Austria, France, Germany, United Kingdom
Phoenix Tissue Repair, Inc.

Completed

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

Recessive Dystrophic Epidermolysis Bullosa

United States
Phoenicis Therapeutics

Terminated

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Epidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, Dominant

United States, Spain, France
Gangnam Severance Hospital
Daewoong Pharmaceutical Co. LTD.

Completed

Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB

Recessive Dystrophic Epidermolysis Bullosa

Korea, Republic of
King's College London
University College, London

Completed

Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa

Recessive Dystrophic Epidermolysis Bullosa

United Kingdom
Stanford University

Completed

Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica

United States
Abeona Therapeutics, Inc
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa | Epidermolysis Bullosa Dystrophica

United States
Holostem Terapie Avanzate s.r.l.
Paracelsus Medical University

Terminated

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB. (HOLOGENE7)

Recessive Dystrophic Epidermolysis Bullosa

Austria
Columbia University

Terminated

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (RDEB)

Epidermolysis Bullosa

United States
University of Southern California

Completed

Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients

Recessive Dystrophic Epidermolysis Bullosa
University of Southern California

Completed

Gentamicin for RDEB

Recessive Dystrophic Epidermolysis Bullosa

United States
King's College London

Unknown

Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa (ADSTEM)

Recessive Dystrophic Epidermolysis Bullosa

United Kingdom
Stanford University

Terminated

Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer

Epidermolysis Bullosa Dystrophica

United States
Abeona Therapeutics, Inc

Completed

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa

United States
Krystal Biotech, Inc.
Stanford University

Withdrawn

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Organogenesis

Terminated

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa, Junctional

United States
Stanford University

Recruiting

A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients (RDEB)

Recessive Dystrophic Epidermolysis Bullosa

United States
Stanford University

Completed

Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care

Epidermolysis Bullosa | Epidermolysis Bullosa Dystrophica

United States
Abeona Therapeutics, Inc

Recruiting

EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | RDEB

United States
University of Southern California

Recruiting

Optimizing IV Gentamicin in JEB

Junctional Epidermolysis Bullosa

United States

Clinical Trials on Epidermolysis Bullosa Simplex Kobner

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations